1Maynard JE. Hepatitis B: global importance and need for control.Vaccine 1990: 8: (Suppl):S18-S20.
2De Jongh FE, Jansen-HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators of hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630-1635.
3Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K,Alexander GJ, Williams R. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-157.
4Dusheiko GM. Treatment and prevention of chronic viral hevatitis. Pharmacol Ther 1995; 65:47-73.
5Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM,Hoofnagle JH. Long term remission of chronic hepatitis B after interferon therapy. Ann Inter Med 1991; 114:629-634.
6Hoofnagle JH, Lau D. Chronic viral hepatitis-benefits of current theravies. N Ene J Med 1996; 334:1470-1471.
7Mazzella G, Saracco G, Festi D, Rosina F, Marchetto S, Jaboli F,Sostegni R, Pezzoli A, Azzaroli F, CanceUieri C, Montagnani M,Roda E, Rizzetto M. Long term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94:2246-2250.
8Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995; 1:7-15.
9Cui L, Yoon S, Schinazi RF, Sommadossi JP. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-de-oxy-2-fluoro-l-beta-D-arabinofuranosyl)-5-iodouracil in human livercells. J Clin Invest 1995; 95:555-563.
10Nicoll A, Locarini S. Review: present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997; 12:843-854.
6Grimm EA, Mazumder A, Zhang HZ,et al. Lymphoklne - activated killer cell phenomenon. Lysis of natural killer - resistant fresh solid tumor cells by interleukin 2 - activated autologous human peripheral blood lymphocytes[ J]. J Med Exp, 1982,155(6) :1823 - 1841.
7Edwards KM, Davis JE, Browne KA, et al. Anti -viral strategies of cytotoxic T lymphocytes are manifested through a variety of granule - bound pathways of apoptosis induction [ J ]. Immunology Cell Biol, 1999,77 ( 1 ) : 76 -89.
8Pena SV, Hanson DA, Carr BA, et al. Processing, subcellular localization, and function of 519 (granulysin), a hu- man late T cell activation molecule with homology to small, lytic, granule proteins [ J ]. J Immunol, 1997,158 (6) :2680 - 2688.
9Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL - 37 and alpha - defensins are expressed by specific lymphocyte and monocyte populations [ J ]. Blood, 2000,96 ( 9 ) : 3086 - 3093.
10Feng Y,Huang N,Wu Q, et al. HMGN2: a novel antimicrobial effector molecule of human mononuclear leukocytes [J]. J Leukoc Biol, 2005, 78(5) :1136-1141.
